Clinical Trials Logo

Filter by:
NCT ID: NCT05669417 Recruiting - Clinical trials for Atrial Fibrillation New Onset

Peri-Operative Magnesium Infusion to Prevent Atrial Fibrillation Evaluated.

POMPAE
Start date: August 1, 2022
Phase: Phase 2/Phase 3
Study type: Interventional

Post-operative atrial fibrillation (POAF) is commonly observed in patients post cardiac surgery without a previous history of atrial fibrillation (AF) or other arrythmias. It's associated with significant postoperative complications including infection, bleeding reoperation, increased hospital length of stay (LOHS) and mortality. Magnesium has been identified as a potentially interesting compound with easy access and low toxicity. Hypomagnesemia has been observed frequently immediately after cardiac surgery. Both reduction of abnormal atomicity of atrial myocardium and prolongation of the atrial refractory period caused by administration of magnesium may prevent AF. The POMPAE trial will analyse the effectiveness of MgSO4 versus placebo (double blind randomized trial) in the prevention of POAF after cardiac surgery.

NCT ID: NCT05669287 Recruiting - Clinical trials for PDAC - Pancreatic Ductal Adenocarcinoma

Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics

Start date: December 22, 2017
Phase: N/A
Study type: Interventional

With CT-perfusion(CTP) it is possible to visualize the enhancement pattern of the tumor. The perfusion CT, interleaved with a routine contrast enhanced CT (CECT) will be performed at diagnosis in all patients (goal: n=125 patients) and at the first follow-up at 3 months in patients treated with systemic therapy (goal: n=50 patients). Also, the histopathology will be collected for resected tumors to perform histopathology analysis. CTP parameters will be correlated to immunohistological findings and clinical outcome. The main goal of the study is to create an AI-assisted method to classify patients with a vascular phenotype of pancreatic ductal adenocarcinoma (PDAC). The investigators expect that this phenotype can be used to predict overall survival and chemotherapy response.

NCT ID: NCT05668988 Recruiting - Clinical trials for Non-small Cell Lung Cancer

A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)

Start date: December 13, 2022
Phase: Phase 3
Study type: Interventional

This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins mutation, who are newly diagnosed or have not received prior systemic therapy in advanced stage. Primary objective of this study is to assess the efficacy of DZD9008 versus platinum-based doublet chemotherapy using by BICR-assessed PFS per RECIST 1.1 as primary endpoint. Approximately 320 participants are estimated to be randomized into the study. Participants enrolled will be randomized to DZD9008 or platinum-based doublet chemotherapy in a 1:1 manner, stratified by baseline brain metastasis (with/without).

NCT ID: NCT05667610 Recruiting - Peanut Allergy Clinical Trials

Immune-supportive Diet and Gut Permeability in Allergic Children

DIAMETER
Start date: September 8, 2022
Phase: N/A
Study type: Interventional

Peanut and nut allergy can be life threatening. Some patients have very low threshold levels (i.e. the amounts of peanut and nuts to which the patients react), others react to higher doses. The reasons for these differences in threshold are not well understood. Patients with peanut and nut allergy often suffer from other allergic diseases (atopic dermatitis, hay fever and asthma). A disturbed gut microbiota composition and an increased gut permeability may explain the development of allergic disease. We hypothesize that increased gut permeability is related to low threshold levels to peanuts or nuts. In addition, as it is known that nutrition can influence our gut permeability, we also hypothesize that a healthful immune-supportive diet restores gut permeability and alleviates symptoms. Therefore, the purpose of the study is to study in peanut and nut allergic children: 1. the relationship between gut permeability and threshold levels to peanut or nuts; 2. the effect of an immune-supportive diet on gut permeability, gut microbiome composition, coexisting allergic symptoms and quality of life

NCT ID: NCT05667454 Recruiting - Progressive Myopia Clinical Trials

MAD Trial: Myopia Atropine Dose

MAD
Start date: December 19, 2022
Phase: Phase 3
Study type: Interventional

The goal of this interventional study is to compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment against progression of axial length in European children with progressive myopia, and to evaluate the safety, adherence, and reasons for nonresponse. Subjects will use Atropine eye drops for a period of 3 years, followed by a 2 year observational period.

NCT ID: NCT05664269 Recruiting - Clinical trials for Muscle Protein Synthesis

Anabolic Properties of Canola

ALPACA
Start date: March 20, 2023
Phase: N/A
Study type: Interventional

Muscle tissue consists of proteins. These proteins are built up of small building blocks: amino acids. By consuming enough protein in our diet, we make sure that the body is provided with enough amino acids to facilitate muscle protein building. Also after exercise is protein intake important as it contributes to the recovery process. Providing the growing world population with sufficient animal-derived protein is a challenge. Plant proteins can be produced on a more sustainable commercial scale than conventional animal-derived proteins and therefore, can contribute to feeding our future population. Canola protein is a protein that is derived from rapeseed. The composition of canola seems to be comparable to that of other high-quality animal-based protein sources. But there is no data yet on the effect of canola protein ingestion on muscle growth. Additionally, most research on the effect of protein intake and muscle growth/recovery has been performed in males and we need more insight into the effect in females. The goal of this study is to investigate whether the ingestion of canola protein can stimulate muscle growth just as good as whey protein after a strength exercise session in females. Primary objective: To assess the impact of 20g canola or 20g whey protein vs placebo ingestion on acute 5-hour postprandial muscle protein synthesis rates during recovery from lower-body resistance-type exercise in vivo in young females. Secondary objective: To assess the impact of 20g canola protein vs 20g whey protein ingestion on acute 5-hour postprandial muscle protein synthesis rates during recovery from lower-body resistance-type exercise in vivo in young females. Tertiary objectives: Compare signaling pathways and. postprandial 5-hour plasma glucose, insulin, and amino acid concentrations, (including area under the curve, peak concentrations, and time to peak) following canola protein, whey protein, and placebo ingestion during recovery from lower-body resistance-type exercise in young females. Hypothesis: it is hypothesized that acute 5-hour postprandial muscle protein synthesis rates will be not different following 20g canola protein and 20g whey protein ingestion and higher compared to placebo during lower-body post-exercise recovery in healthy young females.

NCT ID: NCT05662241 Recruiting - Clinical trials for IgG4 Related Disease

A Phase 3 Study of Obexelimab in Patients With IgG4-Related Disease

INDIGO
Start date: September 30, 2022
Phase: Phase 3
Study type: Interventional

This study aims to examine the efficacy and safety of obexelimab for the prevention of flare of IgG4-related disease (IgG4-RD)

NCT ID: NCT05662111 Recruiting - Fahr Syndrome Clinical Trials

Treatment of Ectopic Calcification in Fahr's Disease or Syndrome

CALCIFADE
Start date: April 3, 2023
Phase: Phase 2
Study type: Interventional

Fahr's disease or syndrome are neurodegenerative diseases in which patients present with bilateral vessel associated calcifications in the basal ganglia. The clinical penetration of Fahr's disease or syndrome is incomplete and heterogeneous comprising of neuropsychiatric signs, cognitive decline, movement disorders, and various other signs (migraine, speech disorders, pain, seizures). The symptoms start between 30 and 50 years and are (slowly) progressive. Symptomatic patients have an increased risk for dependence in activities of daily living and impaired quality of life. Currently, disease-modifying therapies are not available for patients with Fahr's disease or syndrome. However, in a small case series it was shown that alendronate was effective in the clinical treatment of several patients with Fahr's disease or syndrome. Now the time has come to investigate the effectiveness of treatment with bisphosphonates in patients with Fahr's disease or syndrome in a randomized controlled trial.

NCT ID: NCT05660889 Recruiting - Clinical trials for Adrenocortical Carcinoma

Adrenal Vein Sampling as a Tool to Identify Biomarkers That Aid the Diagnosis of Adrenocortical Carcinoma

AVS for ACC
Start date: October 23, 2022
Phase:
Study type: Observational

The goal of this observational pilot study is to explore whether we can identify biomarkers predictive for the diagnosis of adrenocortical carcinoma in blood. Five participants who are suspected to have adrenocortical carcinoma will undergo an adrenal vein sampling in order to obtain a blood sample from the adrenal vein. This blood sample will be analyzed and compared to blood samples taken from the adrenal vein of 20 control patients, which are patients who do not have adrenocortical carcinoma. The blood samples of the control patients will be drawn during routine medical care.

NCT ID: NCT05660226 Recruiting - Hypertension Clinical Trials

Telemonitoring and E-Coaching in Hypertension

TECH
Start date: April 1, 2023
Phase: N/A
Study type: Interventional

Rationale: Hypertension is the most significant risk factor for cardiovascular disease and can be mitigated by lifestyle and medical management. Telemonitoring as a novel management approach to perform hypertension management at distance has been thriving but became indispensable during the COVID-19 pandemic. However, evidence of an effective implementation for telemonitoring remains to be elucidated. Hypothesis: Telemonitoring with a smartphone application, which includes mixed automated services for a personal counselling program (PCP), on top of self-monitoring (SM) will lead to improvement of hypertension control rates, medication adherence and lifestyle behaviors and lower health care costs in patients with hypertension when compared to usual care. Objective: To investigate the effects of PCP+SM on hypertension control rate and lifestyle behaviors as compared with usual care. Study design: The study is a non-blinded randomized controlled clinical trial in adults with hypertension, in a multicenter hospital setting . We will randomize participants in a 1:1 fashion to the intervention group (PCP+SM), or to the control group (usual care). Study population: 400 patients, patients, aged ≥18 years with hypertension (RR >140/90) Main study outcome: hypertension control rate (%<140/90mmHg) after 6 months (as measured by the SPRINT protocol)